TY - JOUR
T1 - Venous thromboembolism (VTE) prophylaxis after bariatric surgery
T2 - a national survey of MBSAQIP director practices
AU - ASMBS Research Committee
AU - Giannopoulos, Spyridon
AU - Kalantar Motamedi, Seyed Mohammad
AU - Athanasiadis, Dimitrios I.
AU - Clapp, Benjamin
AU - Lyo, Victoria
AU - Ghanem, Omar
AU - Edwards, Michael
AU - Puzziferri, Nancy
AU - Stefanidis, Dimitrios
N1 - Funding Information:
The authors would like to thank Mrs Karen Loerzel, support staff of the ASMBS research committee for her help in administering the survey to our participants. Dr. Dimitrios Stefanidis has received institutional research support from Becton Dickinson and Intuitive which are not related to this study. All the authors have no commercial associations that might be a conflict of interest in relation to this article. The authors confirm contribution to the paper as follows: Study conception and design: Stefanidis D, Athanasiadis D. Giannopoulos S, Clapp B. Lyo V. Ghanem O. Puzziferri N, Edwards M; Data collection: Giannopoulos S, Athanasiadis D; Analysis and interpretation of results: Giannopoulos S, Stefanidis D; Kalantar Motamedi SM; Draft preparation: Giannopoulos S; Stefanidis D; Kalantar Motamedi SM; Critical content revision: Stefanidis D. Clapp B. Lyo V. Ghanem O. Puzziferri N;
Publisher Copyright:
© 2023 American Society for Metabolic and Bariatric Surgery
PY - 2023
Y1 - 2023
N2 - Background: Venous thromboembolism (VTE) is the most common cause of death following metabolic/bariatric surgery (MBS), with most events occurring after discharge. The available evidence on ideal prophylaxis type, dosage, and duration after discharge is limited. Objectives: Assess metabolic/bariatric surgeon VTE prophylaxis practices and define existing variability. Setting: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-accredited centers. Methods: The members of the ASMBS Research Committee developed and administered a web-based survey to MBSAQIP medical directors and ASMBS members to examine the differences in clinical practice regarding the administration of VTE prophylaxis after MBS. Results: Overall, 264 metabolic/bariatric surgeons (136 medical directors and 128 ASMBS members) participated in the survey. Both mechanical and chemical VTE prophylaxis was used by 97.1% of the participants, knee-high compression devices by 84.7%, enoxaparin (32.4% 40 mg every 24 hours, 22.7% 40 mg every 12 hours, 24.4% adjusted the dose based on body mass index) by 56.5%, and heparin (46.1% 5000 units every 8 hours, 22.6% 5000 units every 12 hours, 20.9% 5000 units once preoperatively) by 38.1%. Most surgeons (81.6%) administered the first dose preoperatively, while the first postoperative dose was given on the evening of surgery by 44% or the next morning by 42.2%. Extended VTE prophylaxis was prescribed for 2 weeks by 38.7% and 4 weeks by 28.9%. Conclusions: VTE prophylaxis practices vary widely among metabolic/bariatric surgeons. Variability may be related to limited available comparative evidence. Large prospective clinical trials are needed to define optimal practices for VTE risk stratification and prophylaxis in bariatric surgery patients.
AB - Background: Venous thromboembolism (VTE) is the most common cause of death following metabolic/bariatric surgery (MBS), with most events occurring after discharge. The available evidence on ideal prophylaxis type, dosage, and duration after discharge is limited. Objectives: Assess metabolic/bariatric surgeon VTE prophylaxis practices and define existing variability. Setting: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-accredited centers. Methods: The members of the ASMBS Research Committee developed and administered a web-based survey to MBSAQIP medical directors and ASMBS members to examine the differences in clinical practice regarding the administration of VTE prophylaxis after MBS. Results: Overall, 264 metabolic/bariatric surgeons (136 medical directors and 128 ASMBS members) participated in the survey. Both mechanical and chemical VTE prophylaxis was used by 97.1% of the participants, knee-high compression devices by 84.7%, enoxaparin (32.4% 40 mg every 24 hours, 22.7% 40 mg every 12 hours, 24.4% adjusted the dose based on body mass index) by 56.5%, and heparin (46.1% 5000 units every 8 hours, 22.6% 5000 units every 12 hours, 20.9% 5000 units once preoperatively) by 38.1%. Most surgeons (81.6%) administered the first dose preoperatively, while the first postoperative dose was given on the evening of surgery by 44% or the next morning by 42.2%. Extended VTE prophylaxis was prescribed for 2 weeks by 38.7% and 4 weeks by 28.9%. Conclusions: VTE prophylaxis practices vary widely among metabolic/bariatric surgeons. Variability may be related to limited available comparative evidence. Large prospective clinical trials are needed to define optimal practices for VTE risk stratification and prophylaxis in bariatric surgery patients.
KW - Bariatric surgery
KW - Chemoprophylaxis
KW - Mechanical prophylaxis
KW - Survey
KW - Venous thromboembolism (VTE) prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=85147128384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147128384&partnerID=8YFLogxK
U2 - 10.1016/j.soard.2022.12.038
DO - 10.1016/j.soard.2022.12.038
M3 - Article
AN - SCOPUS:85147128384
SN - 1550-7289
JO - Surgery for Obesity and Related Diseases
JF - Surgery for Obesity and Related Diseases
ER -